Biogen passes FDA test for Alzheimer's medicine

The FDA has approved Biogen's Alzheimer's drug, aducanumab.


Pharmaceutical company Biogen's share prices are increasing rapidly on the US stock exchange after the US health authority, the Food and Drug Administration (FDA), approved its Alzheimer's medication on Monday.

Biogen entered the stock exchange before the approval, and in the first minutes of trading after it was obtained, the share price rose by 58 percent to USD 452.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs